company background image
APLS logo

Apellis Pharmaceuticals NasdaqGS:APLS Stock Report

Last Price

US$24.41

Market Cap

US$3.2b

7D

-4.3%

1Y

-57.1%

Updated

18 Mar, 2025

Data

Company Financials +

Apellis Pharmaceuticals, Inc.

NasdaqGS:APLS Stock Report

Market Cap: US$3.2b

APLS Stock Overview

A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. More details

APLS fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Apellis Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Apellis Pharmaceuticals
Historical stock prices
Current Share PriceUS$24.41
52 Week HighUS$59.91
52 Week LowUS$23.77
Beta0.92
1 Month Change-10.91%
3 Month Change-28.25%
1 Year Change-57.12%
3 Year Change-54.90%
5 Year Change-11.33%
Change since IPO73.98%

Recent News & Updates

Apellis Pharmaceuticals (NASDAQ:APLS) Is Making Moderate Use Of Debt

Mar 14
Apellis Pharmaceuticals (NASDAQ:APLS) Is Making Moderate Use Of Debt

Apellis Pharmaceuticals: A Mixed Bag

Mar 05

Recent updates

Apellis Pharmaceuticals (NASDAQ:APLS) Is Making Moderate Use Of Debt

Mar 14
Apellis Pharmaceuticals (NASDAQ:APLS) Is Making Moderate Use Of Debt

Apellis Pharmaceuticals: A Mixed Bag

Mar 05

Apellis: Saved By The October Data

Dec 25

There's No Escaping Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Muted Revenues Despite A 26% Share Price Rise

Dec 15
There's No Escaping Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Muted Revenues Despite A 26% Share Price Rise

Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?

Oct 18
Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?

Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion

Oct 01

Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues

Sep 27
Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues

Apellis: Rare Kidney Disease Data Leads To Possible First To Market

Aug 09

Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

Jul 12
Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

May 30
What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30
It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

May 14

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Feb 16

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

Jul 19
With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

May 13
Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Apr 18
Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Shareholder Returns

APLSUS BiotechsUS Market
7D-4.3%0.6%1.7%
1Y-57.1%-3.0%10.0%

Return vs Industry: APLS underperformed the US Biotechs industry which returned -3% over the past year.

Return vs Market: APLS underperformed the US Market which returned 10% over the past year.

Price Volatility

Is APLS's price volatile compared to industry and market?
APLS volatility
APLS Average Weekly Movement7.3%
Biotechs Industry Average Movement10.6%
Market Average Movement6.5%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market3.4%

Stable Share Price: APLS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: APLS's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009708Cedric Francoisapellis.com

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA.

Apellis Pharmaceuticals, Inc. Fundamentals Summary

How do Apellis Pharmaceuticals's earnings and revenue compare to its market cap?
APLS fundamental statistics
Market capUS$3.15b
Earnings (TTM)-US$197.88m
Revenue (TTM)US$781.37m

3.9x

P/S Ratio

-15.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APLS income statement (TTM)
RevenueUS$781.37m
Cost of RevenueUS$445.29m
Gross ProfitUS$336.07m
Other ExpensesUS$533.95m
Earnings-US$197.88m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.58
Gross Margin43.01%
Net Profit Margin-25.32%
Debt/Equity Ratio198.1%

How did APLS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/18 21:53
End of Day Share Price 2025/03/18 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Apellis Pharmaceuticals, Inc. is covered by 34 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Michael UlzBaird
Ishan MajumdarBaptista Research